FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that as of December 31, 2008, 436 patients were enrolled in the Company’s North American pivotal clinical study for its lead orthopedic product candidate Augment™ Bone Graft. Enrollment is now closed in this study to assess the safety and efficacy of Augment for the treatment of foot and ankle fusions as compared to autograft, the current gold standard for bone grafting in this type of surgery. The study was designed to enroll 396 patients, however enrollment in the trial continued through December 31 to accommodate those additional patients who had already been consented into the study and scheduled for surgery.
